BeOne Medicines (BEIGF) Total Non-Current Liabilities (2015 - 2026)

BeOne Medicines (BEIGF) has reported Total Non-Current Liabilities for 12 consecutive years, with $1.9 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 491.81% year-over-year to $1.9 billion in Q2 2026; TTM through Jun 2026 was $1.9 billion, a 491.81% increase from a year earlier, with the FY2025 full-year figure at $2.0 billion, up 434.67% from the prior year.
• Total Non-Current Liabilities was $1.9 billion for Q2 2026 at BeOne Medicines, down from $2.0 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $2.0 billion in Q4 2025 and troughed at $318.1 million in Q2 2025.
• A 5-year average of $771.1 million and a median of $526.2 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities slumped 34.35% in 2022 and jumped 491.81% in 2026, its largest moves.
• Over 5 years, Total Non-Current Liabilities stood at $527.4 million in 2022, then retreated by 13.19% to $457.8 million in 2023, then fell by 18.36% to $373.8 million in 2024, then soared by 434.67% to $2.0 billion in 2025, then declined by 5.81% to $1.9 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $1.9 billion (Q2 2026), $2.0 billion (Q1 2026), and $2.0 billion (Q4 2025), per Business Quant data.